Enzo Biochem (ENZ) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
23 Nov, 2025Opening remarks and agenda
Meeting called to order at 10:00 A.M. Eastern Time on August 19, 2025, with introductions of key executives and board members.
Outside counsel and Inspector of Election introduced; meeting procedures and participation guidelines outlined.
Board and executive committee updates
Board Chair Steven J. Pully, Directors Bradley Radolph and John Couchman, and executive leadership recognized for their roles.
Board Chair and CEO expressed gratitude to leadership, employees, partners, and shareholders for their support.
Shareholder proposals
Proposal one: Approval of the Agreement and Plan of Merger dated June 23, 2025, and related transactions presented for vote.
No other proposals were presented as only properly noticed business was accepted.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Enzo Biochem
- Revenue fell 20% year-over-year as industry headwinds and cyber settlement impacted results.ENZ
Q3 202518 Jun 2025 - Revenue fell 20%, but losses narrowed and cash position stayed strong.ENZ
Q1 202513 Jun 2025 - Revenue up 3% and gross margin improved; $0.10/share dividend declared.ENZ
Q4 202413 Jun 2025 - Revenue and margins improved, but litigation and cyber risks remain significant.ENZ
Q3 202413 Jun 2025 - Sequential margin gains and narrowed losses amid ongoing legal and NYSE compliance risks.ENZ
Q2 20256 Jun 2025